1. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19;Hammond;N Engl J Med,2022
2. Molnupiravir for oral treatment of Covid-19 in Nonhospitalized Patients;Jayk Bernal;N Engl J Med,2022
3. U.S. Food and Drug Administration, FDA NEWS RELEASE, Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19 2021 [updated December 22, 2021. Available from: 〈https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19〉].
4. Favipiravir: pharmacokinetics and concerns about clinical trials for 2019‐nCoV infection;Du;Clin Pharm Ther,2020
5. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase;Furuta;Proc Jpn Acad, Ser B,2017